Search

Your search keyword '"Spyridonidis A."' showing total 3,829 results
Start Over "Spyridonidis A."

Refine your results

more »

more »

more »

more »

more »

more »

more »

more »
3,829 results on '"Spyridonidis A."'

2. The impact of individual comorbidities in transplant recipients receiving post-transplant cyclophosphamide

Author

Spyridonidis, Alexandros, Labopin, Myriam, Savani, Bipin P., Kulagin, Alexander, Blaise, Didier, Broers, Annoek E. C., Sica, Simona, Raiola, Anna Maria, Vydra, Jan, Choi, Goda, Rovira, Montserrat, Kwon, Mi, Sanz, Jaime, Itäla-Remes, Maija, von dem Borne, Peter, Esquirol, Albert, Koc, Yener, Brissot, Eolia, Nagler, Arnon, Mohty, Mohamad, and Ciceri, Fabio

Published
2025
Full Text
View/download PDF

3. Comparison of fludarabine/melphalan (FM140) with fludarabine/melphalan/BCNU (FBM110) in patients with relapsed/refractory AML undergoing allogeneic hematopoietic cell transplantation – a registry study on behalf of the EBMT Acute Leukemia Working Party

Author

Duque-Afonso, Jesús, Finke, Jürgen, Ngoya, Maud, Galimard, Jacques-Emmanuel, Schetelig, Johannes, Eder, Matthias, Rösler, Wolf, Bug, Gesine, Neubauer, Andreas, Edinger, Matthias, Wulf, Gerald. G., Jindra, Pavel, Einsele, Hermann, Stelljes, Matthias, Selleslag, Dominik, Wagner-Drouet, Eva Maria, Bunjes, Donald, Spyridonidis, Alexandros, Brissot, Eolia, Nagler, Arnon, Ciceri, Fabio, and Mohty, Mohamad

Published
2024
Full Text
View/download PDF

4. Reduced Intensity transplantation vs chemotherapy in CR1. A prospective, pseudorandomized study in 50–70 year old AML patients

Author

Brune, Mats, Kiss, Thomas, Anderson, Harald, Nicklasson, Malin, Delage, Robert, Finke, Jürgen, Gedde-Dahl, Tobias, Hébert, Josée, Höglund, Martin, Kaare, Ain, Lazarevic, Vladimir, Möllgård, Lars, Remes, Kari, Ritchie, David, Spyridonidis, Alexandros, Sabloff, Mitchell, Spearing, Ruth, Wallhult, Elisabeth, and Ljungman, Per

Published
2024
Full Text
View/download PDF

5. Older MRD vs. younger MUD in patients older than 50 years with AML in remission using post-transplant cyclophosphamide

Author

Piemontese, Simona, Labopin, Myriam, Choi, Goda, Broers, Annoek E. C., Peccatori, Jacopo, Meijer, Ellen, Van Gorkom, Gwendolyn, Rovira, Montserrat, Pascual Cascon, Maria Jesús, Sica, Simona, Vydra, Jan, Kulagin, Alexander, Spyridonidis, Alexandros, Nagler, Arnon, Bazarbachi, Ali, Savani, Bipin, Brissot, Eolia, Sanz, Jaime, Mohty, Mohamad, and Ciceri, Fabio

Published
2024
Full Text
View/download PDF

6. Correction: Spyridonidis et al. Effect of Zeolite on the Methane Production from Chicken Manure Leachate. Sustainability 2022, 14, 2207

Author

Apostolos Spyridonidis, Ioanna A. Vasiliadou, and Κaterina Stamatelatou

Subjects
Renewable Energy, Sustainability and the Environment, Geography, Planning and Development, Building and Construction, Management, Monitoring, Policy and Law
Abstract

The authors would like to make the following correction to a typographical error in the published paper [...]

Published
2022
Full Text
View/download PDF

7. Post-transplant cyclophosphamide, calcineurin inhibitor, and mycophenolate mofetil compared to anti-thymocyte globulin, calcineurin inhibitor, and methotrexate combinations as graft-versus-host disease prophylaxis post allogeneic stem cell transplantation from sibling and unrelated donors in patients with acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Author

Nagler, Arnon, Labopin, Myriam, Swoboda, Ryszard, Schroeder, Thomas, Hamladji, Rose-Marie, Griskevicius, Laimonas, Salmenniemi, Urpu, Rambaldi, Alessandro, Mielke, Stephan, Kulagin, Alexander, Passweg, Jakob, Luft, Thomas, Gedde-Dahl, Tobias, Forcade, Edouard, Helbig, Grzegorz, Stelljes, Matthias, Castilla-Llorente, Cristina, Spyridonidis, Alexandros, Brissot, Eolia, Ciceri, Fabio, and Mohty, Mohamad

Published
2024
Full Text
View/download PDF

8. Comparison of fludarabine/melphalan (FluMel) with fludarabine/melphalan/BCNU or thiotepa (FBM/FTM) in patients with AML in first complete remission undergoing allogeneic hematopoietic stem cell transplantation – a registry study on behalf of the EBMT Acute Leukemia Working Party

Author

Duque-Afonso, Jesús, Finke, Jürgen, Ngoya, Maud, Galimard, Jacques-Emmanuel, Craddock, Charles, Raj, Kavita, Bloor, Adrian, Nicholson, Emma, Eder, Matthias, Kim, Orchard, Valerius, Thomas, Snowden, John A., Tholouli, Eleni, Crawley, Charles, Collin, Matthew, Wilson, Keith M. O., Gadisseur, Alain, Protheroe, Rachel, Wagner-Drouet, Eva Maria, Savani, Bipin N., Spyridonidis, Alexandros, Ciceri, Fabio, Nagler, Arnon, and Mohty, Mohamad

Published
2024
Full Text
View/download PDF

9. Validation of the transplant conditioning intensity (TCI) index for allogeneic hematopoietic cell transplantation

Author

Spyridonidis, Alexandros, Labopin, Myriam, Gedde-Dahl, Tobias, Ganser, Arnold, Stelljes, Matthias, Craddock, Charles, Wagner-Drouet, Eva Maria, Versluis, Jurjen, Schroeder, Thomas, Blau, Igor Wolfgang, Wulf, Gerald. G., Dreger, Peter, Olesen, Gitte, Sengeloev, Henrik, Kröger, Nicolaus, Potter, Victoria, Forcade, Edouard, Passweg, Jakob, de Latour, Régis Peffault, Maertens, Johan, Wilson, Keith M. O., Bourhis, Jean Henri, Finke, Juergen, Brissot, Eolia, Bazarbachi, Ali, Giebel, Sebastian, Savani, Bipin P., Nagler, Arnon, Ciceri, Fabio, and Mohty, Mohamad

Published
2024
Full Text
View/download PDF

14. Survival advantage of treosulfan plus fludarabine (FT14) compared to busulfan plus fludarabine (FB4) in active acute myeloid leukemia post allogeneic transplantation: an analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia Working Party (ALWP)

Author

Gavriilaki, Eleni, Sakellari, Ioanna, Labopin, Myriam, Bornhäuser, Martin, Hamladji, Rose-Marie, Casper, Jochen, Edinger, Matthias, Zák, Pavel, Yakoub-Agha, Ibrahim, Ciceri, Fabio, Schroeder, Thomas, Zuckerman, Tsila, Kobbe, Guido, Yeshurun, Moshe, Narni, Franco, Finke, Jürgen, Diez-Martin, Jose Luiz, Berceanu, Ana, Hilgendorf, Inken, Verbeek, Mareike, Olivieri, Attilio, Savani, Bipin, Spyridonidis, Alexandros, Nagler, Arnon, and Mohty, Mohamad

Published
2023
Full Text
View/download PDF

15. Allogeneic hematopoietic cell transplantation for patients with AML aged 70 years or older in first remission. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)

Author

Maffini, Enrico, Ngoya, Maud, Galimard, Jacques-Emmanuel, Harbi, Samia, Kröger, Nicolaus, Platzbecker, Uwe, Sengeloev, Henrik, Craddock, Charles, Potter, Victoria, Choi, Goda, Chevallier, Patrice, Stölzel, Friedrich, Tholouli, Eleni, Maertens, Johan, Ciceri, Fabio, Cornelissen, Jan, Sanz, Jaime, Spyridonidis, Alexandros, Lanza, Francesco, Nagler, Arnon, and Mohty, Mohamad

Published
2023
Full Text
View/download PDF

16. Comparative Study of Mesophilic Biomethane Production in Ex Situ Trickling Bed and Bubble Reactors

Author

Apostolos Spyridonidis and Katerina Stamatelatou

Subjects
biogas upgrading, bio-trickling bed reactor, bubble reactor, mesophilic, hydrogenotrophic methanogenesis, biomethane, Fermentation industries. Beverages. Alcohol, TP500-660
Abstract

Biomethane production via biogas upgrading is regarded as a future renewable gas, further boosting the biogas economy. Moreover, when upgrading is realized by the biogas CO2 conversion to CH4 using surplus renewable energy, the process of upgrading becomes a renewable energy storage method. This conversion can be carried out via microorganisms, and has attracted scientific attention, especially under thermophilic conditions. In this study, mesophilic conditions were imposed using a previously developed enriched culture. The enriched culture consisted of the hydrogenotrophic Methanobrevibacter (97% of the Archaea species and 60% of the overall population). Biogas upgrading took place in three lab-scale bioreactors: (a) a 1.2 L bubble reactor (BR), (b) a 2 L trickling bed reactor (TBR) filled with plastic supporting material (TBR-P), and (c) a 1.2 L TBR filled with sintered glass balls (TBR-S). The gas fed into the reactors was a mixture of synthetic biogas and hydrogen, with the H2 to biogas CO2 ratio being 3.7:1, lower than the stoichiometric ratio (4:1). Therefore, the feeding gas mixture did not make it possible for the CH4 content in the biomethane to be more than 97%. The results showed that the BR produced biomethane with a CH4 content of 91.15 ± 1.01% under a gas retention time (GRT) of 12.7 h, while the TBR-P operation resulted in a CH4 content of 90.92 ± 2.15% under a GRT of 6 h. The TBR-S operated at a lower GRT (4 h), yielding an effluent gas richer in CH4 (93.08 ± 0.39%). Lowering the GRT further deteriorated the efficiency but did not influence the metabolic pathway, since no trace of volatile fatty acids was detected. These findings are essential indicators of the process stability under mesophilic conditions.

Published
2024
Full Text
View/download PDF

18. Haploidentical stem cell donor choice for patients with acute myeloid leukemia: a study from the ALWP of the EBMT

Author

Sanz, Jaime, Labopin, Myriam, Blaise, Didier, Raiola, Anna Maria, Busca, Alessandro, Vydra, Jan, Tischer, Johanna, Chevallier, Patrice, Bramanti, Stefania, Fanin, Renato, Socié, Gérard, Forcade, Edouard, Kröger, Nicolaus, Koc, Yener, Itäla-Remes, Maija, Zecca, Marco, Nagler, Arnon, Brissot, Eolia, Spyridonidis, Alexandros, Bazarbachi, Ali, Giebel, Sebastian, Piemontese, Simona, Mohty, Mohamad, and Ciceri, Fabio

Published
2024
Full Text
View/download PDF

20. Total body irradiation versus busulfan based intermediate intensity conditioning for stem cell transplantation in ALL patients >45 years—a registry-based study by the Acute Leukemia Working Party of the EBMT

Author

Hirschbühl, Klaus, Labopin, Myriam, Polge, Emmanuelle, Blaise, Didier, Bourhis, Jean Henri, Socié, Gerard, Forcade, Edouard, Yakoub-Agha, Ibrahim, Labussière-Wallet, Hélène, Bethge, Wolfgang, Chevallier, Patrice, Bonnet, Sarah, Stelljes, Matthias, Spyridonidis, Alexandros, Peric, Zinaida, Brissot, Eolia, Savani, Bipin, Giebel, Sebastian, Schmid, Christoph, Ciceri, Fabio, Nagler, Arnon, and Mohty, Mohamad

Published
2023
Full Text
View/download PDF

24. Total body irradiation plus fludarabine versus busulfan plus fludarabine as a myeloablative conditioning for adults with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study on behalf of the Acute Leukemia Working Party of the EBMT

Author

Swoboda, Ryszard, Labopin, Myriam, Giebel, Sebastian, Schroeder, Thomas, Kröger, Nicolaus, Arat, Mutlu, Savani, Bipin, Spyridonidis, Alexandros, Hamladji, Rose-Marie, Potter, Victoria, Berceanu, Ana, Yakoub-Agha, Ibrahim, Rambaldi, Alessandro, Ozdogu, Hakan, Sanz, Jaime, Nagler, Arnon, and Mohty, Mohamad

Published
2023
Full Text
View/download PDF

29. Comparative study of treosulfan plus Fludarabine (FT14) with busulfan plus Fludarabine (FB4) for acute myeloid leukemia in first or second complete remission: An analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia Working Party (ALWP)

Author

Gavriilaki, Eleni, Labopin, Myriam, Sakellari, Ioanna, Salmenniemi, Urpu, Yakoub-Agha, Ibrahim, Potter, Victoria, Berceanu, Ana, Rambaldi, Alessandro, Hilgendorf, Inken, Kröger, Nicolaus, Mielke, Stephan, Zuckerman, Tsila, Sanz, Jaime, Busca, Alessandro, Ozdogu, Hakan, Anagnostopoulos, Achilles, Savani, Bipin, Giebel, Sebastian, Bazarbachi, Ali, Spyridonidis, Alexandros, Nagler, Arnon, and Mohty, Mohamad

Published
2022
Full Text
View/download PDF

30. Should anti-thymocyte globulin be added in post-transplant cyclophosphamide based matched unrelated donor peripheral blood stem cell transplantation for acute myeloid leukemia? A study on behalf of the Acute Leukemia Working Party of the EBMT

Author

Spyridonidis, Alexandros, Labopin, Myriam, Brissot, Eolia, Moiseev, Ivan, Cornelissen, Jan, Choi, Goda, Ciceri, Fabio, Vydra, Jan, Reményi, Péter, Rovira, Montserrat, Meijer, Ellen, Labussière-Wallet, Hélène, Blaise, Didier, van Gorkom, Gwendolyn, Kröger, Nicolaus, Koc, Yener, Giebel, Sebastian, Bazarbachi, Ali, Savani, Bipin, Nagler, Arnon, and Mohty, Mohamad

Published
2022
Full Text
View/download PDF

31. Thiotepa-busulfan-fludarabine Compared to Treosulfan-based Conditioning for Haploidentical Transplant With Posttransplant Cyclophosphamide in Patients With Acute Myeloid Leukemia in Remission: A Study From the Acute Leukemia Working Party of the EBMT

Author

Francesco Saraceni, Myriam Labopin, Anna M. Raiola, Didier Blaise, Péter Reményi, Federica Sorà, Jiri Pavlu, Stefania Bramanti, Alessandro Busca, Ana Berceanu, Giorgia Battipaglia, Giuseppe Visani, Gerard Sociè, Gesine Bug, Caterina Micò, Giorgio La Nasa, Maurizio Musso, Attilio Olivieri, Alexandros Spyridonidis, Bipin Savani, Fabio Ciceri, Arnon Nagler, Mohamad Mohty, and on behalf of the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Abstract

We conducted a registry analysis including adult acute myeloid leukemia (AML) patients in remission who had received thiotepa, busulfan, and fludarabine (TBF) or treosulfan-based (Treo) conditioning for haplo-hematopoietic stem cell transplant (HSCT) with posttransplant cyclophosphamide (PTCy) between 2010 and 2020. A total of 1123 patients met the inclusion criteria (968 received TBF and 155 received Treo). A 1:1 matched-pair analysis was performed on 142 TBF and 142 Treo patients. In the Treo group, 68% of patients received treosulfan at a dose ≥36 g/m2 and 54% of patients received a second alkylator (thiotepa or melphalan). We observed a trend toward increased incidence of grade II–IV acute (a) graft-versus-host disease (GVHD) at 180 days in the TBF group compared with Treo (29% versus 20%; P = 0.08), while incidence of grade III–IV aGVHD was not statistically different. Similarly, the incidence of chronic (c) GVHD was not statistically different in the 2 groups. Incidence of nonrelapse mortality at 2 years was 19% in TBF and 14% in Treo (P = 0.4). Relapse incidence at 2 years was not statistically different in the 2 groups (16% and 18% in TBF and Treo, respectively; P = 0.9). Leukemia-free survival, overall survival, and GVHD-free, relapse-free survival was 65% versus 68% (P = 0.6), 73% versus 76% (P = 0.5), and 54% versus 53% (P = 0.8) in TBF versus Treo, respectively. In conclusion, we did not find a significant difference between the 2 conditioning in the present study; Treo and TBF represent 2 valid alternative regimens for haplo-HSCT with PTCy for AML in remission.

Published
2023
Full Text
View/download PDF

32. Hypomethylation-induced regulatory programs in T cells unveiled by transcriptomic analyses

Author

Memnon Lysandrou, Panagiota Stamou, Dionysia Kefala, Chryso Pierides, Maria Kyriakou, Nikolaos Savvopoulos, Panayiota Christofi, Anastasia Papadopoulou, Evangelia Yannaki, Paul Costeas, and Alexandros Spyridonidis

Subjects
regulatory T-cells, hypomethylating agents, HLA-G, RNA-Seq, ScRNA-seq, IDO-1, Immunologic diseases. Allergy, RC581-607
Abstract

Regulatory T cells (Tregs) are essential mediators of tolerance mitigating aberrant immune responses. While naturally occurring Treg (nTreg) development and function are directed by epigenetic events, induced Treg (iTreg) identity and mechanisms of action remain elusive. Mirroring the epigenetic circuits of nTregs, we and others have used hypomethylation agents (HAs) to ex vivo convert T cells into iTregs (HA-iTregs) and further showed that the suppressive properties of the HA-iTregs are predominantly confined in an emergent population, which de novo expresses the immunomodulatory molecule HLA-G, consequently providing a surface marker for isolation of the suppressive HA-iTreg compartment (G+ cells). We isolated the HA-induced G+ cells and their G− counterparts and employed high-throughput RNA-sequencing (RNA-seq) analyses to uncover the G+-specific transcriptomic changes guiding T cells toward a regulatory trajectory upon their exposure to HA. We found a distinct transcriptional upregulation of G+ cells accompanied by enrichment of immune-response–related pathways. Although single-cell RNA-seq profiling revealed regulatory G+ cells to have molecular features akin to nTregs, when assessed in conjunction with the comparative transcriptomic analysis and profiling of secreted cytokines against the non-suppressive G− cells, FOXP3 and other T-helper signatures appear to play a minor role in their suppressive phenotype. We found an ectopic expression of IDO-1 and CCL17/22 in G+ cells, denoting that in vitro exposure of T cells to HA may well unlock myeloid suppressor genes. This report provides transcriptional data shaping the molecular identity of a highly purified and potent HA-iTreg population and hints toward ectopic myeloid-specific molecular mechanisms mediating HA-iTreg function.

Published
2023
Full Text
View/download PDF

34. Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT

Author

Dholaria, Bhagirathbhai, Savani, Bipin N, Labopin, Myriam, Luznik, Leo, Ruggeri, Annalisa, Mielke, Stephan, Malki, Monzr M Al, Kongtim, Piyanuch, Fuchs, Ephraim, Huang, Xiao-Jun, Locatelli, Franco, Aversa, Franco, Castagna, Luca, Bacigalupo, Andrea, Martelli, Massimo, Blaise, Didier, Soussan, Patrick Ben, Arnault, Yolande, Handgretinger, Rupert, Roy, Denis-Claude, O’Donnell, Paul, Bashey, Asad, Solomon, Scott, Romee, Rizwan, Lewalle, Philippe, Gayoso, Jorge, Maschan, Michael, Lazarus, Hillard M, Ballen, Karen, Giebel, Sebastian, Baron, Frederic, Ciceri, Fabio, Esteve, Jordi, Gorin, Norbert-Claude, Spyridonidis, Alexandros, Schmid, Christoph, Ciurea, Stefan O, Nagler, Arnon, and Mohty, Mohamad

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Immunology, Transplantation, Cancer, Regenerative Medicine, Rare Diseases, Prevention, Hematology, Stem Cell Research, Inflammatory and immune system, Consensus, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Humans, Lymphocytes, Prospective Studies, Retrospective Studies, Cardiorespiratory Medicine and Haematology, Cardiovascular medicine and haematology
Abstract

Donor lymphocyte infusion has been used in the management of relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. It can eradicate minimal residual disease or be used to rescue a hematologic relapse, being able to induce durable remissions in a subset of patients. With the increased use of haploidentical hematopoietic cell transplantation, there is renewed interest in the use of donor lymphocytes to either treat or prevent disease relapse post transplant. Published retrospective and small prospective studies have shown encouraging results with therapeutic donor lymphocyte infusion in different haploidentical transplantation platforms. In this consensus paper, finalized on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation, we summarize the available evidence on the use of donor lymphocyte infusion from haploidentical donor, and provide recommendations on its therapeutic, pre-emptive and prophylactic use in clinical practice.

Published
2020

35. Comparative Study of Mesophilic Biomethane Production in Ex Situ Trickling Bed and Bubble Reactors.

Author

Spyridonidis, Apostolos and Stamatelatou, Katerina

Subjects
RENEWABLE natural gas, PLASTICS, GAS mixtures, RENEWABLE energy sources, BIOGAS production, BIOGAS
Abstract

Biomethane production via biogas upgrading is regarded as a future renewable gas, further boosting the biogas economy. Moreover, when upgrading is realized by the biogas CO2 conversion to CH4 using surplus renewable energy, the process of upgrading becomes a renewable energy storage method. This conversion can be carried out via microorganisms, and has attracted scientific attention, especially under thermophilic conditions. In this study, mesophilic conditions were imposed using a previously developed enriched culture. The enriched culture consisted of the hydrogenotrophic Methanobrevibacter (97% of the Archaea species and 60% of the overall population). Biogas upgrading took place in three lab-scale bioreactors: (a) a 1.2 L bubble reactor (BR), (b) a 2 L trickling bed reactor (TBR) filled with plastic supporting material (TBR-P), and (c) a 1.2 L TBR filled with sintered glass balls (TBR-S). The gas fed into the reactors was a mixture of synthetic biogas and hydrogen, with the H2 to biogas CO2 ratio being 3.7:1, lower than the stoichiometric ratio (4:1). Therefore, the feeding gas mixture did not make it possible for the CH4 content in the biomethane to be more than 97%. The results showed that the BR produced biomethane with a CH4 content of 91.15 ± 1.01% under a gas retention time (GRT) of 12.7 h, while the TBR-P operation resulted in a CH4 content of 90.92 ± 2.15% under a GRT of 6 h. The TBR-S operated at a lower GRT (4 h), yielding an effluent gas richer in CH4 (93.08 ± 0.39%). Lowering the GRT further deteriorated the efficiency but did not influence the metabolic pathway, since no trace of volatile fatty acids was detected. These findings are essential indicators of the process stability under mesophilic conditions. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

36. Abstract 15341: A Prospective Study on the Safety and Effectiveness of Apixaban for the Prevention of Thromboembolism in Adults With Congenital Heart Disease and Atrial Arrhythmias: The PROTECT-AR Study

Author

Kartas, Anastasios, Papazoglou, Andreas, Moysidis, Dimitrios, Despotopoulos, Stefanos, Kosmidis, Diamantis, Baroutidou, Amalia, Koutsakis, Athanasios, Liori, Sotiria, Apostolopoulou, Sotiria, Frogoudaki, Alexandra, Tzifa, Afrodite, Galatas, Apostolos, ALEXANDRIDIS, GEORGIOS, Spyridonidis, Efstathios, Doundoulakis, Ioannis, KARAGIANNIDIS, EFSTRATIOS, Karvounis, Charalampos I, Ziakas, Antonios, and Giannakoulas, George

Published
2023
Full Text
View/download PDF

37. P361: HIGH REMISSION AND SURVIVAL RATE IN ADULTS WITH MINIMAL RESIDUAL DISEASE-POSITIVE OR RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA TREATED WITH BLINATUMOMAB IN ROUTINE CLINICAL PRACTICE

Author

Sabina Chiaretti, Sabine Blum, Thibaut Leguay, Marie Balsat, Cyril Salek, Nicola Fracchiolla, Alexandros Spyridonidis, Anita Rijneveld, Cristina Papayannidis, Sofia Ganzha, Reetabrata Bhattacharyya, Gerhard Zugmaier, Isabella Pezzani Grueter, Andreas Ochs, and Alessandro Rambaldi

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2023
Full Text
View/download PDF

38. P1395: PENTAVALENT-SPECIFIC T-CELLS POST HAPLO-IDENTICAL TRANSPLANTATION FOR THE TREATMENT OF OPPORTUNISTIC INFECTIONS

Author

Zoi Bousiou, Ioannis Kyriakou, Georgios Karavalakis, Chrysa Pantazi, Maria Liga, Ioanna Vallianou, Maria Giannaki, Kyriakos Koukoulias, Elena Zotou, Ioannis Batsis, Anna Vardi, Apostolia Papalexandri, Foteini Kika, Alexandros Spyridonidis, Ioanna Sakellari, Anastasia Papadopoulou, and Evangelia Yannaki

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2023
Full Text
View/download PDF

39. P1360: CLINICAL TRANSLATION OF A NOVEL, POTENT AND WELL-CHARACTERIZED INDUCED REGULATORY T-CELL PRODUCT AGAINST GRAFT VERSUS HOST DISEASE

Author

Memnon Lysandrou, Dionysia Kefala, Panayiota Christofi, Penelope Georgia Papagianni, Antonis Mingos, Chryso Pieridou, Elisavet Vlachonikola, Maria Kyriakou, Alexandra Lydia Chatzidaniil, Nikolaos Savvopoulos, Anastasia Papadopoulou, Anastasia Chatzidimitriou, Paul Costeas, Evangelia Yannaki, and Alexandros Spyridonidis

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2023
Full Text
View/download PDF

41. Comparison of fludarabine–melphalan and fludarabine–treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation—a registry study on behalf of the EBMT Acute Leukemia Working Party

Author

Duque-Afonso, Jesus, Finke, Jürgen, Labopin, Myriam, Craddock, Charles, Protheroe, Rachel, Kottaridis, Panagiotis, Tholouli, Eleni, Byrne, Jenny L., Orchard, Kim, Salmenniemi, Urpu, Hilgendorf, Inken, Hunter, Hannah, Nicholson, Emma, Bloor, Adrian, Snowden, John A., Verbeek, Mareike, Clark, Andrew, Savani, Bipin N., Spyridonidis, Alexandros, Nagler, Arnon, and Mohty, Mohamad

Published
2022
Full Text
View/download PDF

42. Impact of conditioning regimen intensity on outcomes of second allogeneic hematopoietic cell transplantation for secondary acute myelogenous leukemia

Author

Nagler, Arnon, Peczynski, Christophe, Dholaria, Bhagirathbhai, Labopin, Myriam, Valerius, Thomas, Dreger, Peter, Kröger, Nicolaus, Reinhardt, Hans Christian, Finke, Jürgen, Franke, Georg-Nikolaus, Ciceri, Fabio, Verbeek, Mareike, Blau, Igor Wolfgang, Bornhäuser, Martin, Spyridonidis, Alexandros, Bug, Gesine, Bazarbachi, Ali, Schmid, Christophe, Yakoub-Agha, Ibrahim, Savani, Bipin N., and Mohty, Mohamad

Published
2022
Full Text
View/download PDF

43. Augmented FLAMSA-Bu versus FluBu2 reduced-intensity conditioning in patients with active relapsed/refractory acute myeloid leukemia: an EBMT analysis

Author

Rodríguez-Arbolí, Eduardo, Labopin, Myriam, Eder, Matthias, Brecht, Arne, Blau, Igor Wolfgang, Huynh, Anne, Forcade, Edouard, Tischer, Johanna, Bethge, Wolfgang, Bondarenko, Sergey, Verbeek, Mareike, Bulabois, Claude Eric, Einsele, Hermann, Stölzel, Friedrich, Savani, Bipin, Spyridonidis, Alexandros, Bazarbachi, Ali, Giebel, Sebastian, Brissot, Eolia, Schmid, Christoph, Nagler, Arnon, and Mohty, Mohamad

Published
2022
Full Text
View/download PDF

44. Gilteritinib as Post-Transplant Maintenance for Acute Myeloid Leukemia With Internal Tandem Duplication Mutation of FLT3

Author

Levis, M, Hamadani, M, Logan, B, Jones, R, Singh, A, Litzow, M, Wingard, J, Papadopoulos, E, Perl, A, Soiffer, R, Ustun, C, Ueda Oshima, M, Uy, G, Waller, E, Vasu, S, Solh, M, Mishra, A, Muffly, L, Kim, H, Mikesch, J, Najima, Y, Onozawa, M, Thomson, K, Nagler, A, Wei, A, Marcucci, G, Geller, N, Hasabou, N, Delgado, D, Rosales, M, Hill, J, Gill, S, Nuthethi, R, King, D, Wittsack, H, Mendizabal, A, Devine, S, Horowitz, M, Chen, Y, Agura, E, Altman, J, Anagnostopoulos, A, Anand, S, Artz, A, Aulitzky, W, Balderman, S, Ballen, K, Becker, M, Beguin, Y, Berkahn, L, Berneman, Z, Bhatt, V, Bilmon, I, Bonifazi, F, Briggs, A, Bruno, B, Brunstein, C, Byrne, M, Byrne, J, Cabrero, M, Cairoli, R, Carrum, G, Cerny, J, Cheong, J, Ciceri, F, Colorado, M, Cook, R, Couriel, D, Craddock, C, Damon, L, Deol, A, Desbrosses, Y, Di Grazia, C, Di Stasi, A, Dias, A, Dorritie, K, Essell, J, Eto, T, Farag, S, Forcade, E, Frankfurt, O, Fujiwara, S, Fukuda, T, Fukushima, K, Furst, S, Goto, T, Hall, A, Hatta, S, Hicheri, Y, Horwitz, M, Hou, H, How, J, Howard, D, Hsu, W, Huynh, A, Irvine, D, Ishikawa, T, Jamieson, K, Jedrzejczak, W, Jethava, Y, Jimenez, A, Jung, C, Kanda, J, Karakasis, D, Kato, J, Kekre, N, Khera, N, Klein, A, Kobbe, G, Kornblit, B, Kota, V, Lachance, S, Leber, B, Lee, C, Lee, J, Lin, T, Liu, T, Martelli, M, Martinez, C, Matsuoka, K, Mccarty, J, Mendez, L, Michelis, F, Mineishi, S, Mohty, M, Moors, I, Motyckova, G, Mueller, L, Nakamae, H, Nakano, N, Nathan, S, Nicholson, E, Norkin, M, Ogawa, Y, Olesen, G, Oluwole, O, Pantin, J, Paulson, K, Pemberton, L, Perera, T, Piatkowska-Jakubas, B, Poire, X, Protheroe, R, Rambaldi, A, Ritchie, D, Ross, K, Rubio, M, Santarone, S, Sanz Caballer, J, Sawa, M, Schaar, D, Scheid, C, Schriber, J, Seropian, S, Shah, N, Shore, T, Gil, J, Sobecks, R, Socie, G, Sprague, K, Spyridonidis, A, Stelljes, M, Stiff, P, Stuart, R, Tanaka, M, Tandra, A, Tholouli, E, Thomas, X, Tiribelli, M, Tomlinson, B, Tsirigotis, P, Tzachanis, D, Uchida, N, Ueda, M, Valcarcel Ferreiras, D, Wagner, E, Watson, A, Weisdorf, D, Wolschke, C, Wrobel, T, Yakoub-Agha, I, Yamauchi, T, Yared, J, Yeh, S, Yoon, S, Yoshihara, S, Null, N, Levis, Mark J., Hamadani, Mehdi, Logan, Brent, Jones, Richard J., Singh, Anurag K., Litzow, Mark, Wingard, John R., Papadopoulos, Esperanza B., Perl, Alexander E., Soiffer, Robert J., Ustun, Celalettin, Ueda Oshima, Masumi, Uy, Geoffrey L., Waller, Edmund K., Vasu, Sumithra, Solh, Melhem, Mishra, Asmita, Muffly, Lori, Kim, Hee-Je, Mikesch, Jan-Henrik, Najima, Yuho, Onozawa, Masahiro, Thomson, Kirsty, Nagler, Arnon, Wei, Andrew H., Marcucci, Guido, Geller, Nancy L., Hasabou, Nahla, Delgado, David, Rosales, Matt, Hill, Jason, Gill, Stanley C., Nuthethi, Rishita, King, Denise, Wittsack, Heather, Mendizabal, Adam, Devine, Steven M., Horowitz, Mary M., Chen, Yi-Bin, Agura, Ed, Altman, Jessica, Anagnostopoulos, Achiles, Anand, Sarah, Artz, Andrew, Aulitzky, Walter, Balderman, Sophia, Ballen, Karen, Becker, Michael, Beguin, Yves, Berkahn, Leanne, Berneman, Zwi, Bhatt, Vijaya, Bilmon, Ian, Bonifazi, Francesca, Briggs, Adrienne, Bruno, Benedetto, Brunstein, Claudio, Byrne, Michael, Byrne, Jenny, Cabrero, Monica, Cairoli, Roberto, Carrum, George, Cerny, Jan, Cheong, June-Won, Ciceri, Fabio, Colorado, Mercedes, Cook, Rachel, Couriel, Daniel, Craddock, Charles, Damon, Lloyd, Deol, Abhinav, Desbrosses, Yohan, Devine, Steve, Di Grazia, Carmela, Di Stasi, Antonio, Dias, Ajoy, Dorritie, Kathy, Essell, James, Eto, Tetsuya, Farag, Sherif, Forcade, Edouard, Frankfurt, Olga, Fujiwara, Shinichiro, Fukuda, Takahiro, Fukushima, Kentaro, Furst, Sabine, Goto, Tatsunori, Hall, Aric, Hatta, Shunsuke, Hicheri, Yosr, Horwitz, Mitchell, Hou, Hsin-An, How, Jonathan, Howard, Dianna, Hsu, Wei-Hsun (Blake), Huynh, Anne, Irvine, David, Ishikawa, Takayuki, Jamieson, Katarzyna, Jedrzejczak, Wieslaw, Jethava, Yogesh, Jimenez, Antonio, Jung, Chul Won, Kanda, Junya, Karakasis, Dimitrios, Kato, Jun, Kekre, Natasha, Khera, Nandita, Klein, Andreas, Kobbe, Guido, Kornblit, Brian, Kota, Vamsi, Lachance, Silvy, Leber, Brian, Lee, Catherine, Lee, Je Hwan, Lin, Tung-Liang, Liu, Ta-Chih, Martelli, Maurizio, Martinez, Carmen, Matsuoka, Kenichi, McCarty, John, Mendez, Lourdes, Michelis, Fotios, Mineishi, Shin, Mohty, Mohamad, Moors, Ine, Motyckova, Gabriela, Mueller, Lutz, Nakamae, Hirohisa, Nakano, Nobuaki, Nathan, Sunita, Nicholson, Emma, Norkin, Maxim, Ogawa, Yoshiaki, Olesen, Gitte, Oluwole, Olalekan, Pantin, Jeremy, Paulson, Kristjan, Pemberton, Lucy, Perera, Travis, Piatkowska-Jakubas, Beata, Poire, Xavier, Protheroe, Rachel, Rambaldi, Alessandro, Ritchie, David, Ross, Kelly, Rubio, Marie-Therese, Santarone, Stella, Sanz Caballer, Jaime, Sawa, Masashi, Schaar, Dale, Scheid, Christoph, Schriber, Jeffrey, Seropian, Stuart, Shah, Nilay, Shah, Nirav, Shore, Tsiporah, Gil, Jorge Sierra, Singh, Anurag, Sobecks, Ronald, Socie, Gerard, Soiffer, Robert, Sprague, Kellie, Spyridonidis, Alexandros, Stelljes, Matthias, Stiff, Patrick, Stuart, Robert, Tanaka, Masatsugu, Tandra, Anand, Tholouli, Eleni, Thomas, Xavier, Tiribelli, Mario, Tomlinson, Benjamin, Tsirigotis, Panagiotis, Tzachanis, Dimitrios, Uchida, Naoyuki, Ueda, Masumi, Valcarcel Ferreiras, David, Wagner, Eva, Watson, Anne-Marie, Weisdorf, Daniel, Wolschke, Christine, Wrobel, Tomasz, Yakoub-Agha, Ibrahim, Yamauchi, Takuji, Yared, Jean, Yeh, Su-Peng, Yoon, Sung-Soo, Yoshihara, Satoshi, null, null, Levis, M, Hamadani, M, Logan, B, Jones, R, Singh, A, Litzow, M, Wingard, J, Papadopoulos, E, Perl, A, Soiffer, R, Ustun, C, Ueda Oshima, M, Uy, G, Waller, E, Vasu, S, Solh, M, Mishra, A, Muffly, L, Kim, H, Mikesch, J, Najima, Y, Onozawa, M, Thomson, K, Nagler, A, Wei, A, Marcucci, G, Geller, N, Hasabou, N, Delgado, D, Rosales, M, Hill, J, Gill, S, Nuthethi, R, King, D, Wittsack, H, Mendizabal, A, Devine, S, Horowitz, M, Chen, Y, Agura, E, Altman, J, Anagnostopoulos, A, Anand, S, Artz, A, Aulitzky, W, Balderman, S, Ballen, K, Becker, M, Beguin, Y, Berkahn, L, Berneman, Z, Bhatt, V, Bilmon, I, Bonifazi, F, Briggs, A, Bruno, B, Brunstein, C, Byrne, M, Byrne, J, Cabrero, M, Cairoli, R, Carrum, G, Cerny, J, Cheong, J, Ciceri, F, Colorado, M, Cook, R, Couriel, D, Craddock, C, Damon, L, Deol, A, Desbrosses, Y, Di Grazia, C, Di Stasi, A, Dias, A, Dorritie, K, Essell, J, Eto, T, Farag, S, Forcade, E, Frankfurt, O, Fujiwara, S, Fukuda, T, Fukushima, K, Furst, S, Goto, T, Hall, A, Hatta, S, Hicheri, Y, Horwitz, M, Hou, H, How, J, Howard, D, Hsu, W, Huynh, A, Irvine, D, Ishikawa, T, Jamieson, K, Jedrzejczak, W, Jethava, Y, Jimenez, A, Jung, C, Kanda, J, Karakasis, D, Kato, J, Kekre, N, Khera, N, Klein, A, Kobbe, G, Kornblit, B, Kota, V, Lachance, S, Leber, B, Lee, C, Lee, J, Lin, T, Liu, T, Martelli, M, Martinez, C, Matsuoka, K, Mccarty, J, Mendez, L, Michelis, F, Mineishi, S, Mohty, M, Moors, I, Motyckova, G, Mueller, L, Nakamae, H, Nakano, N, Nathan, S, Nicholson, E, Norkin, M, Ogawa, Y, Olesen, G, Oluwole, O, Pantin, J, Paulson, K, Pemberton, L, Perera, T, Piatkowska-Jakubas, B, Poire, X, Protheroe, R, Rambaldi, A, Ritchie, D, Ross, K, Rubio, M, Santarone, S, Sanz Caballer, J, Sawa, M, Schaar, D, Scheid, C, Schriber, J, Seropian, S, Shah, N, Shore, T, Gil, J, Sobecks, R, Socie, G, Sprague, K, Spyridonidis, A, Stelljes, M, Stiff, P, Stuart, R, Tanaka, M, Tandra, A, Tholouli, E, Thomas, X, Tiribelli, M, Tomlinson, B, Tsirigotis, P, Tzachanis, D, Uchida, N, Ueda, M, Valcarcel Ferreiras, D, Wagner, E, Watson, A, Weisdorf, D, Wolschke, C, Wrobel, T, Yakoub-Agha, I, Yamauchi, T, Yared, J, Yeh, S, Yoon, S, Yoshihara, S, Null, N, Levis, Mark J., Hamadani, Mehdi, Logan, Brent, Jones, Richard J., Singh, Anurag K., Litzow, Mark, Wingard, John R., Papadopoulos, Esperanza B., Perl, Alexander E., Soiffer, Robert J., Ustun, Celalettin, Ueda Oshima, Masumi, Uy, Geoffrey L., Waller, Edmund K., Vasu, Sumithra, Solh, Melhem, Mishra, Asmita, Muffly, Lori, Kim, Hee-Je, Mikesch, Jan-Henrik, Najima, Yuho, Onozawa, Masahiro, Thomson, Kirsty, Nagler, Arnon, Wei, Andrew H., Marcucci, Guido, Geller, Nancy L., Hasabou, Nahla, Delgado, David, Rosales, Matt, Hill, Jason, Gill, Stanley C., Nuthethi, Rishita, King, Denise, Wittsack, Heather, Mendizabal, Adam, Devine, Steven M., Horowitz, Mary M., Chen, Yi-Bin, Agura, Ed, Altman, Jessica, Anagnostopoulos, Achiles, Anand, Sarah, Artz, Andrew, Aulitzky, Walter, Balderman, Sophia, Ballen, Karen, Becker, Michael, Beguin, Yves, Berkahn, Leanne, Berneman, Zwi, Bhatt, Vijaya, Bilmon, Ian, Bonifazi, Francesca, Briggs, Adrienne, Bruno, Benedetto, Brunstein, Claudio, Byrne, Michael, Byrne, Jenny, Cabrero, Monica, Cairoli, Roberto, Carrum, George, Cerny, Jan, Cheong, June-Won, Ciceri, Fabio, Colorado, Mercedes, Cook, Rachel, Couriel, Daniel, Craddock, Charles, Damon, Lloyd, Deol, Abhinav, Desbrosses, Yohan, Devine, Steve, Di Grazia, Carmela, Di Stasi, Antonio, Dias, Ajoy, Dorritie, Kathy, Essell, James, Eto, Tetsuya, Farag, Sherif, Forcade, Edouard, Frankfurt, Olga, Fujiwara, Shinichiro, Fukuda, Takahiro, Fukushima, Kentaro, Furst, Sabine, Goto, Tatsunori, Hall, Aric, Hatta, Shunsuke, Hicheri, Yosr, Horwitz, Mitchell, Hou, Hsin-An, How, Jonathan, Howard, Dianna, Hsu, Wei-Hsun (Blake), Huynh, Anne, Irvine, David, Ishikawa, Takayuki, Jamieson, Katarzyna, Jedrzejczak, Wieslaw, Jethava, Yogesh, Jimenez, Antonio, Jung, Chul Won, Kanda, Junya, Karakasis, Dimitrios, Kato, Jun, Kekre, Natasha, Khera, Nandita, Klein, Andreas, Kobbe, Guido, Kornblit, Brian, Kota, Vamsi, Lachance, Silvy, Leber, Brian, Lee, Catherine, Lee, Je Hwan, Lin, Tung-Liang, Liu, Ta-Chih, Martelli, Maurizio, Martinez, Carmen, Matsuoka, Kenichi, McCarty, John, Mendez, Lourdes, Michelis, Fotios, Mineishi, Shin, Mohty, Mohamad, Moors, Ine, Motyckova, Gabriela, Mueller, Lutz, Nakamae, Hirohisa, Nakano, Nobuaki, Nathan, Sunita, Nicholson, Emma, Norkin, Maxim, Ogawa, Yoshiaki, Olesen, Gitte, Oluwole, Olalekan, Pantin, Jeremy, Paulson, Kristjan, Pemberton, Lucy, Perera, Travis, Piatkowska-Jakubas, Beata, Poire, Xavier, Protheroe, Rachel, Rambaldi, Alessandro, Ritchie, David, Ross, Kelly, Rubio, Marie-Therese, Santarone, Stella, Sanz Caballer, Jaime, Sawa, Masashi, Schaar, Dale, Scheid, Christoph, Schriber, Jeffrey, Seropian, Stuart, Shah, Nilay, Shah, Nirav, Shore, Tsiporah, Gil, Jorge Sierra, Singh, Anurag, Sobecks, Ronald, Socie, Gerard, Soiffer, Robert, Sprague, Kellie, Spyridonidis, Alexandros, Stelljes, Matthias, Stiff, Patrick, Stuart, Robert, Tanaka, Masatsugu, Tandra, Anand, Tholouli, Eleni, Thomas, Xavier, Tiribelli, Mario, Tomlinson, Benjamin, Tsirigotis, Panagiotis, Tzachanis, Dimitrios, Uchida, Naoyuki, Ueda, Masumi, Valcarcel Ferreiras, David, Wagner, Eva, Watson, Anne-Marie, Weisdorf, Daniel, Wolschke, Christine, Wrobel, Tomasz, Yakoub-Agha, Ibrahim, Yamauchi, Takuji, Yared, Jean, Yeh, Su-Peng, Yoon, Sung-Soo, Yoshihara, Satoshi, and null, null

Abstract

PURPOSEAllogeneic hematopoietic cell transplantation (HCT) improves outcomes for patients with AML harboring an internal tandem duplication mutation of FLT3 (FLT3-ITD) AML. These patients are routinely treated with a FLT3 inhibitor after HCT, but there is limited evidence to support this. Accordingly, we conducted a randomized trial of post-HCT maintenance with the FLT3 inhibitor gilteritinib (ClinicalTrials.gov identifier: NCT02997202) to determine if all such patients benefit or if detection of measurable residual disease (MRD) could identify those who might benefit.METHODSAdults with FLT3-ITD AML in first remission underwent HCT and were randomly assigned to placebo or 120 mg once daily gilteritinib for 24 months after HCT. The primary end point was relapse-free survival (RFS). Secondary end points included overall survival (OS) and the effect of MRD pre- and post-HCT on RFS and OS.RESULTSThree hundred fifty-six participants were randomly assigned post-HCT to receive gilteritinib or placebo. Although RFS was higher in the gilteritinib arm, the difference was not statistically significant (hazard ratio [HR], 0.679 [95% CI, 0.459 to 1.005]; two-sided P =.0518). However, 50.5% of participants had MRD detectable pre- or post-HCT, and, in a prespecified subgroup analysis, gilteritinib was beneficial in this population (HR, 0.515 [95% CI, 0.316 to 0.838]; P =.0065). Those without detectable MRD showed no benefit (HR, 1.213 [95% CI, 0.616 to 2.387]; P =.575).CONCLUSIONAlthough the overall improvement in RFS was not statistically significant, RFS was higher for participants with detectable FLT3-ITD MRD pre- or post-HCT who received gilteritinib treatment. To our knowledge, these data are among the first to support the effectiveness of MRD-based post-HCT therapy.

Published
2024

45. Ultrasound-guided femoral approach for coronary angiography and interventions in the porcine model

Author

Grigorios Tsigkas, Georgios Vasilagkos, Alexandros Tousis, Michail Theofanis, Anastasios Apostolos, Ioannis Spyridonidis, Leonidas Goudas, Georgios Karpetas, Athanasios Moulias, Christos S. Katsouras, Panagiotis Kitrou, Virginia Mplani, Anargyros N. Moulas, Dimitrios Karnabatidis, and Periklis Davlouros

Subjects
Medicine, Science
Abstract

Abstract Coronary angiography and percutaneous coronary intervention (PCI) procedural details in swine are similar to those performed to humans, since their heart and coronary anatomy closely resembles. However, only a few detailed descriptions of the procedure are available, containing notable differences. We present a feasible and reproducible protocol for percutaneous coronary interventions in porcine experimental models, utilizing ultrasound-guided femoral approach. Nine female pigs were studied to explore the feasibility of superficial femoral arterial (SFA) access for coronary angiography and provisional PCI, as well as the most suitable guiding coronary catheters and angiographic projections for the above interventions. Experiments were performed under general anesthesia, using ultrasound-guided puncture of the SFA to gain arterial access. The Amplatzer AR1® catheter, and the Right Coronary Bypass® catheter were used for the selective engagement of the right and the left coronary artery, respectively. Successful arterial access and subsequent cardiac catheterization were performed in all pigs. Only one animal required a second puncture for femoral artery access. None of the 9 animals presented any significant tachycardia or hypotensive episode. One animal developed an access site-related complication following the first catheterization procedure. During follow-up, 100% success of SFA catheterization was achieved using the same ultrasound-guided technique. The ultrasound-guided superficial femoral artery access for coronary angiography and provisional interventions in porcine models is a quick and safe alternative to the carotid artery approach. The RCB and AR1 catheters may be the best choice for the quick and easy selective coronary engagement of the right and left ostia, respectively.

Published
2022
Full Text
View/download PDF

46. Total body irradiation plus fludarabine versus thiotepa, busulfan plus fludarabine as a myeloablative conditioning for adults with acute lymphoblastic leukemia treated with haploidentical hematopoietic cell transplantation. A study by the Acute Leukemia Working Party of the EBMT

Author

Swoboda, Ryszard, Labopin, Myriam, Giebel, Sebastian, Angelucci, Emanuele, Arat, Mutlu, Aljurf, Mahmoud, Sica, Simona, Pavlu, Jiri, Socié, Gerard, Bernasconi, Paolo, Rigacci, Luigi, Tischer, Johanna, Risitano, Antonio, Rovira, Montserrat, Saccardi, Riccardo, Pioltelli, Pietro, Van Gorkom, Gwendolyn, Vitek, Antonin, Savani, Bipin N., Spyridonidis, Alexandros, Peric, Zinaida, Nagler, Arnon, and Mohty, Mohamad

Published
2022
Full Text
View/download PDF

48. Study protocol: Phase I/II trial of induced HLA-G+ regulatory T cells in patients undergoing allogeneic hematopoietic cell transplantation from an HLA-matched sibling donor

Author

Memnon Lysandrou, Dionysia Kefala, Panayiota Christofi, Nikolaos Savvopoulos, Penelope Georgia Papayanni, Rodanthy Theodorellou, Eleftheria Sagiadinou, Vassiliki Zacharioudaki, Maria Moukouli, Dimitrios Tsokanas, Georgios Karavalakis, Maria Liga, Konstantinos Stavrinos, Anastasia Papadopoulou, Evangelia Yannaki, and Alexandros Spyridonidis

Subjects
allogeneic hematopoietic cell transplantation, graft versus host disease, adoptive cellular immunotherapy, regulatory T cells, HLA-G, hypomethylating agents, Medicine (General), R5-920
Abstract

Regulatory T-cell (Treg) immunotherapy has emerged as a promising and highly effective strategy to combat graft-versus-host disease (GvHD) after allogeneic hematopoietic cell transplantation (allo-HCT). Both naturally occurring Treg and induced Treg populations have been successfully evaluated in trials illustrating the feasibility, safety, and efficacy required for clinical translation. Using a non-mobilized leukapheresis, we have developed a good manufacturing practice (GMP)-compatible induced Treg product, termed iG-Tregs, that is enriched in cells expressing the potent immunosuppressive human leucocyte antigen-G molecule (HLA-G+). To assess the safety and the maximum tolerable dose (MTD) of iG-Tregs, we conduct a phase I–II, two-center, interventional, dose escalation (3 + 3 design), open-label study in adult patients undergoing allo-HCT from an HLA-matched sibling donor, which serves also as the donor for iG-Treg manufacturing. Herein, we present the clinical protocol with a detailed description of the study rationale and design as well as thoroughly explain every step from patient screening, product manufacturing, infusion, and participant follow-up to data collection, management, and analysis (registered EUDRACT-2021-006367-26).

Published
2023
Full Text
View/download PDF

49. FIRST-IN-HUMAN PHASE I/II CLINICAL TRIAL OF IG-TREGS FOR GVHD PREVENTION

Author

Lysandrou, M., primary, Kefala, D., additional, Christofi, P., additional, Liga, M., additional, Miggos, A., additional, Papagregoriou, C., additional, Vlachonikola, E., additional, Savvopoulos, N., additional, Zacharioudaki, V., additional, Vallianou, I., additional, Sagiadinou, E., additional, Tsokanas, D., additional, Theodorelou, R., additional, Papadopoulou, A., additional, Triantafyllou, E., additional, Sakellari, I., additional, Costeas, P., additional, Chatzidimitriou, A., additional, Yannaki, E., additional, and Spyridonidis, A., additional

Published
2024
Full Text
View/download PDF

50. Abstract No. 341 Yttrium-90 (Y90) Radiation Lobectomy or Bi-/Tri-segmentectomy for Large Inoperable Liver Tumors

Author

Dimopoulos, M., primary, Spyridonidis, T., additional, Giannikas, N., additional, Spyridonidis, I., additional, Kitrou, P., additional, Nistikoulis, G., additional, Anagnostopoulos, f., additional, Taki, V., additional, Christodoulou, E., additional, Theofanis, M., additional, Chaniotaki, N., additional, Papageorgiou, C., additional, Karnabatidis, D., additional, and Katsanos, K., additional

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results